1. Pink Sheet

CMS Offers Part D Plans Financial Backstop If Rebates Eliminated In 2020

 
• By Cathy Kelly

But CMS also advises Medicare Part D plans to develop bids for the 2020 plan year that include rebates, since the final version of the HHS rule eliminating the anti-kickback safe harbor for rebates may not be released in time for the June 3 bid submission deadline. 

rebate - cube with letters, sign with wooden cubes

Medicare Part D plans may be able to participate in a “demonstration” over the next two years that would help cushion the financial impact of an HHS rule to eliminate drug rebates by revising the anti-kickback safe harbor that currently protects them.

“If there is a change in the safe harbor rules effective in 2020, [the Centers for Medicare and Medicaid Services] will conduct a demonstration that would test an efficient transition for beneficiaries and plans to such a change in the Part D program,” CMS told plan sponsors in an April 5

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Brazil To Upgrade Pricing Framework To Keep Up With Market Developments

 
• By Francesca Bruce

Brazil plans to clarify its medicine pricing framework, for example by outlining the procedures for setting medicine prices and bring it up to date with recent developments in the sector.

England: HTA Sandbox Helping To Assess ‘Challenging’ Drugs And Indications

 
• By Eliza Slawther

England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 
• By Neena Brizmohun

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.